Rigel's bleeding disorder drug fails late-stage study

(Reuters) - Rigel Pharmaceuticals Inc said its lead drug to treat a bleeding disorder failed in a second late-stage trial, sending its shares tumbling 32 percent in premarket trading on Thursday.